HDA 2026 Traceability Seminar: The New Challenge Is Interoperability
DSCSA compliance is no longer the finish line. As the pharmaceutical supply chain enters an era of sustained operation, the focus is shifting from implementation to operational effectiveness, inspection readiness, exception management, and ecosystem-wide interoperability. […]
When Distribution Models Change Faster Than Controls: GLP-1, DTC, and the New Pharmaceutical Risk Landscape
Within this slide deck, you can explore how GLP-1 demand, telehealth, digital pharmacies, and direct-to-consumer distribution are reshaping the pharmaceutical supply chain and creating new patient safety and security challenges. Rx-360’s Ryan Kelly, Interim CEO […]
Supplier Assessment Questionnaire (SAQ) Guide
TURN INSIGHT INTO ACTION WITH THE RX‑360 SAQ GUIDE The Rx‑360 Supplier Assessment Questionnaire (SAQ) Guide provides a practical walkthrough of how to effectively use the SAQ within your supplier qualification program. Designed as a […]
Rx-360 DSCSA Readiness Checklist for Distributors
Wholesale distributors play a pivotal role in safeguarding the integrity of the U.S. pharmaceutical supply chain under the Drug Supply Chain Security Act (DSCSA). The Rx‑360 DSCSA Readiness Checklist for Distributors distills core requirements into […]
Rx‑360 DSCSA Readiness Checklist for Manufacturers
Ensuring full compliance with the Drug Supply Chain Security Act (DSCSA) is essential for maintaining product integrity, meeting FDA expectations, and enabling seamless interoperability across the pharmaceutical supply chain. The Rx‑360 DSCSA Readiness Checklist for […]
Supplier Corrective Action Report Web Form
Optimize Supplier Corrective Actions with Rx‑360’s SCAR Template The Supplier Quality Working Group at Rx‑360 has developed a standardized Supplier Corrective Action Report (SCAR) template designed to strengthen pharmaceutical supply chain integrity and improve quality […]
Rx-360 Reaffirms Compliance with NMPA Requirements | Download the Position Letter
Rx-360 is committed to supporting the global pharmaceutical industry in meeting regulatory standards worldwide. In response to the National Medical Products Administration (NMPA) release of Appendices One and Two of Article 310 of the Good […]